(L) has hypertension or high blood pres-
sure; 
(M) has a neurological condition such as 
dementia or Parkinson’s Disease; 
(N) has liver disease; 
(O) is pregnant; 
(P) has pulmonary fibrosis; 
(Q) has thalassemia; 
(R) is a smoker; 
(S) has a disability; or 
(T) meets any other characteristic identi-
fied by the Centers for Disease Control and 
Prevention as putting individuals at increased 
risk of developing severe illness from COVID– 
19. 
(6) INCARCERATED PERSON.—The term ‘‘incar-
cerated person’’ means an individual involuntarily 
confined or detained in a correctional facility. 
(7) SIGNS AND SYMPTOMS OF COVID–19.—The 
term ‘‘signs and symptoms of COVID–19’’ means 
fever or chills, cough, shortness of breath or dif-
ficulty breathing, fatigue, muscle or body aches, 
headache, new loss of taste or smell, sore throat, 
congestion or runny nose, nausea or vomiting, diar-
rhea, and any other medical condition or reaction 
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS
identified by the Centers for Disease Control and 
Prevention as being a physical reaction to the con-
traction of the severe acute respiratory syndrome 
coronavirus 2 (SARS–CoV–2). 
SEC. 3. MANDATED COVID–19 TESTING AND VACCINATION 
AT CORRECTIONAL FACILITIES. 
(a) TESTING OF INCARCERATED PERSONS.— 
(1) IN
GENERAL.—Each correctional facility 
shall— 
(A) not later than 15 days after the date 
of enactment of this Act— 
(i) provide each incarcerated person in 
the facility with the option to take a 
COVID–19 diagnostic test, regardless of 
whether the incarcerated person exhibits 
symptoms of COVID–19, at no cost to the 
incarcerated person; 
(ii) provide each incarcerated person 
with the results of the diagnostic test, re-
gardless of the results, including an inter-
pretation of what the test results mean in 
the incarcerated person’s preferred lan-
guage; 
(iii) provide each incarcerated person 
who tests positive for COVID–19 with nec-
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS
essary medical care (as outlined in the Na-
tional Institutes of Health COVID–19 
Treatment Guidelines), including COVID– 
19 tests to monitor recovery if indicated by 
the Centers for Disease Control and Pre-
vention, and housing in a medical isolation 
unit under the care of medical profes-
sionals, at no cost to the incarcerated per-
son; 
(iv) place each asymptomatic incarcer-
ated person who is exposed to a positive 
case in quarantine until testing is com-
pleted consistent with Centers for Disease 
Control and Prevention guidance; and 
(v) place each symptomatic incarcer-
ated person into medical isolation while 
awaiting test results; and 
(B) during the period beginning not later 
than 45 days after the date of enactment of 
this Act and ending on the last day of the 
COVID–19 pandemic— 
(i) conduct weekly COVID–19 diag-
nostic testing of incarcerated persons in 
the facility in accordance with the guide-
lines developed under section 6, regardless 
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS
of whether such incarcerated persons ex-
hibit symptoms of COVID–19, at no cost 
to incarcerated persons; 
(ii) conduct COVID–19 diagnostic 
testing for any incarcerated person with 
COVID–19 symptoms, or for any incarcer-
ated person who is a close contact of a 
known COVID–19 case, in accordance with 
the guidelines developed under section 6; 
(iii) provide each incarcerated person 
with the results of the diagnostic tests, re-
gardless of the results, including an inter-
pretation of what the test results mean in 
the incarcerated person’s preferred lan-
guage; 
(iv) provide each incarcerated person 
who tests positive for COVID–19 with nec-
essary medical care (as outlined in the Na-
tional Institutes of Health COVID–19 
Treatment Guidelines), including COVID– 
19 tests to monitor recovery if indicated by 
the Centers for Disease Control and Pre-
vention, and housing in a medical isolation 
unit under the care of medical profes-
sionals, at no cost to the incarcerated per-
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS
son, in accordance with the guidelines de-
veloped under section 6; 
(v) quarantine each incarcerated per-
son exposed to a positive COVID–19 case 
in accordance with the guidelines developed 
under section 6; and 
(vi) establish a procedure through 
which incarcerated people can opt out of 
COVID–19 testing, in accordance with the 
guidelines developed under section 6. 
(2) NEW ENTRANTS.—During the period begin-
ning not later than 45 days after the date of enact-
ment of this Act and ending on the last day of the 
COVID–19 pandemic, each correctional facility 
shall— 
(A) provide each incarcerated person newly 
admitted or transferred to the facility with an 
optional COVID–19 diagnostic test within 24 
hours of entering the facility, regardless of 
whether the incarcerated person exhibits symp-
toms of COVID–19, at no cost to the incarcer-
ated person; and 
(B) immediately quarantine each incarcer-
ated person newly admitted or transferred to 
the facility within 24 hours of entering the fa-
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS
cility, consistent with Centers for Disease Con-
trol and Prevention guidance, until the incar-
cerated person has been confirmed to be nega-
tive for COVID–19, in accordance with the 
guidelines developed under section 6. 
(b) TESTING OF CORRECTIONAL FACILITY EMPLOY-
EES.— 
(1) IN
GENERAL.—Each correctional facility 
shall— 
(A) not later than 15 days after the date 
of enactment of this Act— 
(i) provide each correctional facility 
employee with a required COVID–19 diag-
nostic test, regardless of whether the em-
ployee exhibits symptoms of COVID–19, at 
no cost to the employee; and 
(ii) provide each correctional facility 
employee who tests positive for COVID–19 
with unlimited paid administrative leave 
for 
the 
purpose 
of 
recovering 
from 
COVID–19, and no cost COVID–19 diag-
nostic testing for the purpose of moni-
toring recovery if indicated by the Centers 
for Disease Control and Prevention, until 
VerDate Sep 11 2014 
02:56 Jun 02, 2021
Jkt 019200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H2293.IH
H2293
pbinns on DSKJLVW7X2PROD with BILLS